BOSTON, Feb. 2, 2015 /PRNewswire/ --Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that it will present at the upcoming 17th Annual BIO CEO & Investor Conference, to be held at the Waldorf Astoria in New York City. Columbia's CEO, Frank Condella, will present at the conference at 1:00pm on February 9th in the Duke of Windsor room.
To access a live webcast of the presentation, visit http://www.veracast.com/webcasts/bio/ceoinvestor2015/04117292104.cfm
The webcast will be available until May 10, 2015.
About Columbia Laboratories
Columbia Laboratories, Inc. has a successful heritage in developing women's health focused pharmaceutical products, including CRINONE® 8% (progesterone gel), that is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide. Columbia is leveraging its pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to advance an internal pipeline while generating revenue from pharmaceutical industry customers. For more information, please visit www.columbialabs.com.
CRINONE® is a registered trademark of Actavis, Inc. in the U.S.
Investor Relations Contact:
MBS Value Partners
+212 661 7004
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/columbia-laboratories-to-present-at-the-17th-annual-bio-ceo--investor-conference-300028533.html
SOURCE Columbia Laboratories, Inc.